49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

103 trials found

diseases per page:

Showing 1 to 10 of 103 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04893161 (ClinicalTrials.gov)	March 31, 2022	16/5/2021	A Model About the Response of Belimumab in SLE	A Model to Early Predict the Response of BelimumabTreatment in the Patients With Systemic Lupus Eryt ...	Systemic Lupus Erythematosus	Drug: Belimumab	First Affiliated Hospital Xi'an Jiaotong University	NULL	Not yet recruiting	18 Years	N/A	All	72	Phase 4	NULL
2	NCT05262686 (ClinicalTrials.gov)	March 10, 2022	22/2/2022	Efficacy and Immunological Evaluation of BelimumabPlus Low Dose IL-2 in the Treatment of Systemic Lu ...	Efficacy and Immunological Evaluation of BelimumabPlus Low Dose IL-2 in the Treatment of Systemic Lu ...	Systemic Lupus Erythematosus	Drug: Belimumab;Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	70 Years	All	10	Phase 3	China
3	NCT04908865 (ClinicalTrials.gov)	October 29, 2021	26/5/2021	Open-label Study of BelimumabPlus Standard Therapy in Chinese Pediatric Participants With Active Sys ...	A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of BelimumabPlus ...	Systemic Lupus Erythematosus	Drug: Belimumab;Drug: Standard therapy	GlaxoSmithKline	NULL	Not yet recruiting	5 Years	17 Years	All	65	Phase 4	NULL
4	EUCTR2021-001802-30-DE (EUCTR)	28/10/2021	02/09/2021	Efficacy of the drug Benlysta (active ingredient: belimumab) to improve cardiac abnormalities in pat ...	Efficacy of belimumabto improve subclinical cardiovascular abnormalitiesusing imaging endpoints with ...	Efficacy of belimumabto improve subclinical cardiovascular abnormalities using imaging endpoints wit ...	Trade Name: Benlysta ®	Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	56	Phase 4	Germany
5	JPRN-jRCTs021210042	14/10/2021	14/10/2021	Randomized , double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and saf ...	Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safe ...	Systemic Lupus Erythematosus : SLE Systemic Lupus Erythematosus, SLE;D008180	Group A to which the test drug is administered and Group B to which the placebo is administered will ...	Ishii Tomonori	NULL	Recruiting	>= 20age old	< 80age old	Both	30	N/A	Japan
6	NCT04956484 (ClinicalTrials.gov)	September 1, 2021	8/7/2021	Belimumab In Treatment of Early Systemic Lupus Erythematosus	A Single-center, Randomized, Open Label, 52-week Study of BelimumabIn Treatment of Early Systemic Lu ...	Lupus Erythematosus, Systemic	Biological: Belimumab;Drug: Standard of care	Peking Union Medical College Hospital	NULL	Not yet recruiting	18 Years	75 Years	All	84	Phase 4	China
7	ChiCTR2100043138	2021-04-01	2021-02-05	Efficacy of belimumabcombined with standard of care in patients with untreated systemic lupus erythe ...	Efficacy of belimumabcombined with standard of care in patients with untreated systemic lupus erythe ...	Systemic lupus erythematosus	Belimumab+SoC group:Belimumab+SoC;SoC group:SoC;	Affiliated Hospital of Guilin Medical College	NULL	Recruiting	16	65	Both	Belimumab+SoC group:40;SoC group:40;	Phase 4	China
8	NCT04515719 (ClinicalTrials.gov)	March 19, 2021	13/8/2020	Efficacy and Safety of Belimumab in SLE Patients	Efficacy and Safety of Belimumabfor Prevention of Disease Flares in SLE Patients With Low Disease Ac ...	Systemic Lupus Erythematosus	Biological: Belimumab;Biological: Placebo	RenJi Hospital	NULL	Recruiting	18 Years	70 Years	All	334	Phase 4	China
9	NCT04570306 (ClinicalTrials.gov)	December 31, 2020	19/6/2020	Transcriptional and Immine Parameters of Response to Belinumab	Whole Blood Transcriptional and Mass Cytometry Immune Profiling in Systemic Lupus Erythematosus (SLE ...	Systemic Lupus Erythematosus	Drug: Belimumab	Biomedical Research Foundation, Academy of Athens	NULL	Not yet recruiting	18 Years	65 Years	All	80		NULL
10	NCT04447053 (ClinicalTrials.gov)	September 2020	23/6/2020	Sequential Belimumab and T-cell Based Therapy in SLE	Sequential BelimumabFollowed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosu ...	Systemic Lupus Erythematosus	Drug: Belimumab Injection [Benlysta]	National University Hospital, Singapore	GlaxoSmithKline	Not yet recruiting	21 Years	70 Years	All	80	Phase 4	Singapore

First Previous1 2 3 4 5…11Next Last